180 Life Sciences Corp SEC Filings

Welcome to our dedicated page for 180 Life Sciences SEC filings (Ticker: ATNFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

180 life sciences corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. its product development platforms in phase iib/iii clinical trials include fibrosis and anti-tnf platform, which focuses on fibrosis and anti-tumor necrosis factors; synthetic cannabidiol (cbd) analogs platform, which are man-made derivatives of cbd; and a7nachr platform, which focuses on alpha 7 nicotinic acetylcholine receptor. the company is headquartered in menlo park, california.